Case Info
Dupixent May Increase the Risk for Cutaneous T-cell Lymphomas
Dupixent (dupilumab) is an injectable biologic medication used to treat certain types of inflammatory diseases. It is a monoclonal antibody that works by targeting the interleukin 4 receptor to treat the underlying cause of inflammation.
It is approved to treat people with:
- Atopic dermatitis
- Eczema
- Asthma
- Chronic sinusitis
- Eosinophilic esophagitis
Recent studies have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis
Fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication. People who used Dupixent and were later diagnosed with CTCL or one of the subtypes may be eligible for compensation
Cutaneous T-cell Lymphoma Cancer Development
As part of the immune system, skin plays a major role in the lymphatic system. Certain cancers of the lymph system are known as Lymphomas.
Cutaneous T-cell Lymphoma is a type of cancer that originates in the skin. It is one of the non-Hodgkins Lymphoma group of cancers that affects a type of white blood cell known as T-cells.
CTCL may include subtypes of Cutaneous T-cell Lymphoma including Sezary Syndrome, Mycosis Fungoides, and other T-cell Lymphoma subtypes which begin in the skin.
Symptoms of CTCL may include:
- Itching
- Red, scaly, or thickened patches of skin
- Peeling skin
- Discolored skin
- Raised bumps or nodules
- Skin sores or ulcers
- Hair loss
- Enlarged lymph nodes
Some symptoms of CTCL may be similar to the diseases that Dupixent is used to treat.
Studies Show Dupixent May Increase Risk of CTCL
Studies published in dermatologic medical journals since 2022 and more recently in 2024 and 2025, showed that Dupixent may increase the risk of development of CTCL. Multiple retrospective cohort studies showed that patients who used Dupixent for the treatment of atopic dermatitis may have an increased risk of CTCL development when compared to patients who were treated with other medications. The risk appeared to be highest in the first year after beginning treatment with Dupixent and may be as high as 3 to 4.5 times greater in Dupixent patients.
Though the exact mechanism for increased CTCL cancer risk with Dupixent use is unknown, in some cases, Dupixent may have hidden undetected CTCL when it was used to treat conditions with similar symptoms to cancer or may have worsened existing cancers.
Drug Manufacturers May Have Known About Risks
Dupixent manufacturers Regeneron Pharmaceuticals and Sanofi have been accused of manufacturing a dangerous medication. In addition, they may have known about the risks of CTCL, Mycosis Fungioides and Sezary syndrome in patients who use Dupixent for atopic dermatitis and other inflammatory disorders and failed to warn patients and the medical community about the risks of their medication
People or loved ones of those who took Dupixent for conditions such as eczema, atopic dermatitis, or other conditions and later developed Cutaneous T-cell Lymphoma (CTCL), Sezary Syndrome, or Mycosis Fungoides may be eligible for compensation.